Targeting Human Immunodeficiency Virus Type 1 Assembly, Maturation and Budding
The targets for licensed drugs used for the treatment of human immunodeficiency virus type 1 (HIV-1) are confined to the viral reverse transcriptase (RT), protease (PR), and the gp41 transmembrane protein (TM). While currently approved drugs are effective in controlling HIV-1 infections, new drug ta...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
AboutScience Srl
2007-01-01
|
| Series: | Drug Target Insights |
| Online Access: | https://doi.org/10.1177/117739280700200020 |